Litcius/Paper detail

Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

Yan Zhao, Litao Zhang, Yangfeng Ding, Xiaohua Tao, Chao Ji, Xiuqin Dong, Jianyun Lu, Liming Wu, Rupeng Wang, Qianjin Lu, Aik Han Goh, Rongjun Liu, Zhiguo Zhang, Jianzhong Zhang

2021American Journal of Clinical Dermatology58 citationsDOIOpen Access PDF

Topics & Concepts

MedicineEczema Area and Severity IndexAtopic dermatitisPlaceboInternal medicineClinical endpointAdverse effectRandomized controlled trialDermatology Life Quality IndexJanus kinase inhibitorClinical trialGastroenterologyDermatologyJanus kinaseDiseasePathologyCytokineAlternative medicineDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisMast cells and histamine
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial | Litcius